Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BACKGROUND: Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Renhua, Chen, Xiaofen, Wang, Tongshan, Zhang, Zhiyuan, Sun, Jin, Shu, Yongqian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058104/
https://www.ncbi.nlm.nih.gov/pubmed/21366910
http://dx.doi.org/10.1186/1471-2407-11-90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058104/
https://www.ncbi.nlm.nih.gov/pubmed/21366910
http://dx.doi.org/10.1186/1471-2407-11-90

Ejemplares similares